Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Feb 19, 2009

Premium

Title: Intracellular Expression and Delivery of siRNAs in Mammalian Cells

Number: 20090042207

Filed: Aug. 21, 2008

Lead Inventor: David Engelke, University of Michigan

The invention, the patent application's abstract states, "relates to compositions and methods for intracellular expression and delivery of siRNAs in mammalian cells. The siRNA is transcribed intracellularly as a double-stranded RNA of about 18 to about 25 base pairs long from an expression cassette. Intracellular expression of siRNA is effective at reducing or eliminating expression of the targeted genes, and is applicable to reverse genetic analysis of genes and to genetic therapy, as for example to inhibiting expression of pathogenic genes and oncogenes."


Title: Uses of Broad Spectrum RNAi Therapeutics Against Influenza

Number:
20090042823

Filed: Aug. 11, 2008

Lead Inventor: Michael Templin, Nastech Pharmaceutical (MDRNA)

The patent application, its abstract states, claims "methods and uses of RNAi-inducing agents for medicaments and [for] treating or preventing a viral infection."

Specifically, the application claims a method of preventing or treating influenza caused by a drug-resistant strain of the virus using RNAi-inducing agents.


Title: Methods and Compositions for Treating Gain-of-Function Disorders Using RNA Interference

Number: 20090042828

Filed: July 17, 2008

Lead Inventor: Zuoshang Xu, University of Massachusetts (RXi Pharmaceuticals)

The invention "relates to novel methods for treating dominant gain-of-function diseases," the patent application's abstract states. "The invention provides methods for targeting regions of the copper zinc superoxide dismutase, which causes inherited amyotrophic lateral sclerosis, with [an] RNAi agent. The invention further provides RNAi-resistant replacement genes containing mismatches with their respective RNAi agents. The invention also provides for vectors that express RNAi agent and RNAi-resistant replacement gene of the … invention."


Title: Methods and Compositions for the Specific Inhibition of Gene Expression by Double-Stranded RNA

Number: 20090043083, 20090043085

Filed: June 12 & 20, 2008

Lead Inventor: John Rossi, City of Hope (Integrated DNA Technologies)

"The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene," the patent applications' abstracts state. "More particularly, the invention is directed to compositions that contain double-stranded RNA, and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery."


Title: siRNA Targeting Minichromosome Maintenance Deficient 3

Number: 20090043084

Filed: June 6, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to MCM3."

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.